AVIR · Atea Pharmaceuticals, Inc.

Summary

Atea Pharmaceuticals, Inc. reported fourth quarter and full year 2025 financial results, including a net loss of $44.9 million ($0.57 per share) for Q4 and $158.3 million ($1.94 per share) for the year, with cash and investments of $301.8 million as of December 31, 2025. The company provided updates on its Phase 3 HCV program with topline results expected mid-2026 and year-end 2026, and announced clinical development of AT-587 for HEV starting mid-2026.